Variability in aggregometry response before and after initiation of clopidogrel therapy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 6, 2009, Pages 673-679

  Meen, Øystein ^a   Brosstad, Frank ^b   Bjørnsen, Stine ^b   Pedersen, Turid Margrethe ^b   Erikssen, Gunnar ^c  

^a Department of Medicine

^b Research Institute for Internal Medicine   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clopidogrel; Clopidogrel resistance; Intraindividual variations; Methodology; Percutaneous coronary intervention; Platelet aggregometry

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RELIABILITY; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ASPIRIN; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REPRODUCIBILITY OF RESULTS; TICLOPIDINE;

EID: 72949086665     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365510902971875     Document Type: Article

References (40)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, T ognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
2. Mehta SR, Yusuf S, P eters RJ, B ertrand ME, L ewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, Copland I, Fox KAA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533
3. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420
4. Rocca B, P atrono C. D eterminants of the inter individual variability in response to antiplatelet drugs. J Thromb Haemost. 2005;3:1597-1602
5. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5(Suppl. 1): 230-237
6. Gurbel PA, T antry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol. 2006; 19:439-448
7. Lerkevang GE, H vas A-M, K ristensen SD. A spirin resistance: myth or major problem? Scand J Clin Lab Invest. 2008;68:257-259
8. Gurbel PA, T antry US. Clopidogrel resistance? T hromb Res. 2007;120:311-321
9. Angiolillo DJ, Fernandez-Ortiz A, B ernardo E, R amirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004;25:1903-1910
10. Kastrati A, von BN, J oost A, P ogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110:1916-1919
11. Muller I, Seyfarth M, Rudiger S, Wolf B, P ogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93 (Pubitemid 32973418)
12. von BN, T aubert D, P ogatsa-Murray G, S chomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946-2950
13. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006;3:387-395
14. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharmacological Research. 2006;23:2691-2708.
15. Cesari F, M arcucci R, Caporale R, P anniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930-935
16. Angiolillo DJ, F ernandez-Ortiz A, Bernardo E, R amirez C, Cavallari U, Trabetti E, Sabate M, Jiminez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos Costa MA, Bass TA, Pignatti PF, Macaya C. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005;116:491-497
17. Fontana P, D upont A, Gandrille S, B achelot-Loza C, R eny J-L, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108:989-995
18. Angiolillo DJ, B ernardo E, P alazuelos J, D esai B, W eisberg I, Alfonso F, Guzman LA, Hernandez-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost. 2008;99:161-168
19. Bliden KP, D iChiara J, T antry US, B assi AK, C haganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666
20. Gurbel PA, Bliden KP, Hiatt BL, O 'Connor CM. C lopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913
21. Matetzky S, F efer P, S henkman B, V aron D, S avion N, Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol. 2008;102:524-529
22. Serebruany VL. T he 'clopidogrel resistance' trap. A m J Cardiol. 2007;100:1044-1046
23. Snoep JD, Hovens MM, Eikenboom JC, v an der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-231
24. Dropinski J, Jakiela B, S anak M, Wegrzyn W, B iernat M, Dziedzina S, Plutecka H, Szczeklik. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost. 2007;98:201-209
25. Eikelboom JW, H ankey GJ, T hom J, Claxton A, Y i Q, Gilmore G, Staton J, Barden A, Norman PE. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost. 2005;3:2649-2655
26. Frelinger AL, III, Furman MI, L inden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclo oxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888-2896
27. Gurbel PA, Bliden KP, D iChiara J, N ewcomer J, W eng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156-3164
28. Lev EI, Patel RT, M aresh KJ, G uthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.
29. Ohmori T, Yatomi Y, Nonaka T, Kobayashi T, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006;4:1271-1278
30. Patrono C, C oller B, F itzGerald GA, Hirsh J, R oth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl. ):234S-64S.
31. Meen O, Brosstad F, K hiabani H, G jertsen E, L auritsen ME, Pedersen TM, Bjornsen S, Schjelderup NM, Ameln W, Chye E, Wettergren M, Siddique SP, Erikssen G. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2007;67:1-10.
32. Mortensen J, Poulsen TS, G rove EL, R efsgaard J, Ladefoged Nielsen H, Bendesgaard Pederesen S, Sommer Thygesen S, Hvas A-M, Dalby Kristensen S. Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest. 2008;68:786-792
33. Geiger J, T eichmann L, Grossmann R, A ktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005;51:957-965
34. Gurbel PA, Becker RC, M ann KG, S teinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-1834
35. Breddin HK. Can platelet aggregometry be standardized? Platelets. 2005;16:151-158
36. Opper C, W einer N, Xu F, A dam W, F ruhstorfer H, Wesemann W. Daily variations of functional parameters and density distribution in human blood platelets. Chronobiol Int. 1994;11:309-319
37. Muller I, Besta F, Schulz C, M assberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787
38. Macchi L, C hristiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002;107:45-49
39. Sibbing D, von BO, S chomig A, K astrati A, v on BN. P latelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis. 2007;18:335-339
40. Braun OO, Amisten S, Wihlborg AK, H unting K, Nilsson D, Erlinge D. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). Purinergic Signal. 2007;3:195-201.